Longeveron Inc获中国专利授权,用于评估人间充质干细胞效力的测定方法

美股速递
Apr 08

生物技术公司Longeveron Inc宣布,其用于评估人间充质干细胞产品效力的关键测定方法已获得中国国家知识产权局颁发的专利授权。此项专利涵盖了该公司开发的专用检测技术,旨在精确量化MSCs的治疗潜力与生物学活性,为细胞治疗产品的标准化与质量控制提供重要工具。该专利的获批有望强化Longeveron在中国细胞治疗领域的知识产权布局,并支持其相关细胞疗法产品的临床开发与商业化进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10